Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder (BACLOPHONE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02596763|
Recruitment Status : Recruiting
First Posted : November 4, 2015
Last Update Posted : August 25, 2020
BACLOPHONE is a prospective multicenter cohort study, conducted in two nearby French regions (Hauts-de-France and Normandie). BACLOPHONE consists of the monthly phone-based monitoring of 792 patients during their first year of baclofen prescription for alcohol use disorder.
The main objective of the study is to determine the rate of patients who stop baclofen due to an adverse event (AE) in the first year of treatment.The BACLOPHONE study also aims to determine which types of AEs and serious AEs are actually liable to baclofen, and which other types are more likely the consequence of confounding factors, e.g., concomitant alcohol, psychotropic medications or substance uses, and comorbidities.
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Use Disorder||Drug: Baclofen||Phase 4|
Inclusions are performed by any previously-labeled baclofen-prescribing physician in the Hauts-de-France or Normandie French regions.
INITIAL ASSESSMENT PHONE CALLS
In the 15 days following the inclusion, participants will receive two successive phone calls. The first call will be performed by a physician investigator of the study who will: re-explain the principles of the study to patients, check the absence of non-inclusion criteria, and note the medical history, date of baclofen initiation and current dose, undergoing medications and current doses, occurrence of AEs since the initiation of baclofen, birthdate, weight, and height. The physician will also check whether specific safety elements important with regards to the baclofen treatment are noticeable in the patient: history of seizures, suicide, and other concurrent substance use. The second phone call is performed by a clinical research associate (CRA) who will check the absence of non-inclusion criteria, and collects the 30 last-days reported alcohol use according to alcohol timeline follow-back (A-TLFB) method, date of initiation and current dose of baclofen, severity alcohol dependence questionnaire (SADQ), alcohol use disorder identification test (AUDIT), and A-B neuropsychological assessment schedule (ABNAS) which scores the current level of sedation in patients with psychotropic drugs.
FOLLOW-UP PHONE CALLS
During the subsequent one-year follow-up, two types of phone interviews are performed: 1) Monthly Standardized Interviews (MSI). MSIs consist in collecting the previous-month daily use of alcohol using the A-TLFB, the daily dose of baclofen across the previous month, the current ABNAS sedation score, any change in any associated medication, any change in any substance use, and any AE reported by the patient. No predefined list of AEs is used, as the investigator only asks the patient if he/she has noticed or experienced any unexpected symptoms of health issues since the last call. The daily dose distribution of baclofen, i.e., hours and doses of baclofen intakes, are also systematically investigated in the patient. The average subjective level of craving for alcohol is self-scored by the patient using a 0-10 verbal rating scale (i.e., 0 for no craving at all, to 10 for the most severe possible craving). The daily hours of maximum craving is also noted.
2) Semi-standardized Pharmacovigilance Interviews (SPI) which are unscheduled, and are performed in the case of an AE reported by the patient to the CRA, or in the case of a direct phone call to the pharmacovigilance center by the patient or their baclofen prescriber, with the aim to report an AE. Data collected are: current baclofen dose and recent changes in baclofen dosing, recent and current drinking patterns, associated medications, type of AE, 'serious' feature of the AE according to the definition of the Food and Drugs Administration, onset date and occurrence conditions. Patients can be secondarily re-contacted to assess the final outcome of the AE, and to determine the causality score of baclofen regarding the AE, using both the French causality method and the Naranjo's algorithm if applicable.
DELAYED PHONE CALL IN THE CASE OF BACLOFEN CESSATION
If baclofen is stopped for any reason during the year following the initiation, a last phone interview will be conducted by the CRA 3 months after baclofen cessation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||792 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phone-based Safety Monitoring of the First Year of Baclofen Treatment for Alcohol Use Disorder: the BACLOPHONE Cohort Study|
|Study Start Date :||December 2015|
|Estimated Primary Completion Date :||January 2022|
|Estimated Study Completion Date :||January 2022|
Patient with current alcohol use disorder included by any baclofen prescriber located in the French region of Nord - Pas-de-Calais - Picardie.
Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
Other Name: Agonist of GABA B receptors
- Discontinuation of baclofen because of an AE [ Time Frame: First year of treatment ]The link between AE and the discontinuation of baclofen will be defined by the results of the analysis of the pharmacovigilance team. the one-year probability (with it 95% confidence interval) of baclofen discontinuation due to the occurrence of an AE will be estimated using the Kaplan-Meier method. Drop-outs, death, or baclofen discontinuation for other reasons than an AE will be treated as censoring events. A sensitivity analysis treating death or baclofen discontinuation for other reasons than an AE as competing risk will be performed using the approach of Kalbfleisch and Prentice.
- Frequency of the different types of AEs and SAEs occuring on baclofen [ Time Frame: First year of treatment ]The AEs will be identified and reported by the "Monthly Standardized CRA Phone Interviews" and by the "Unscheduled pharmacovigilance Phone Interviews".
- Relationship between the occurrence of the first sedative AE and alcohol and baclofen dosing [ Time Frame: First year of treatment ]To determine whether there is an association between the occurrence of baclofen-related sedation and the concurrent doses of baclofen, alcohol and psychoactive drugs. , bivariate and multivariate time-varying Cox's regression models will be used to assess the impact of doses of baclofen and alcohol on occurrence of first sedative AE by using available exposition measures.
- Causality of baclofen in the occurrence each AE [ Time Frame: First year of treatment ]To determine the causality of baclofen in the occurrence of each AE, using the French method for assessing causality, and the Naranjo's algorithm (if applicable). For each AE, the determined causality of baclofen will thus be "doubtful", "possible", "probable", and "definite"
- Proportion of patients whose prescription meets the official prescription requirements of the Temporary Recommendation for Use (TRU) [ Time Frame: First year of treatment ]This proportion of patients will be calculated from data collected during "Monthly Standardized CRA Phone Interviews", based on whether the patient has received the official TRU document which should systematically be given together with the prescription
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02596763
|Contact: Benjamin ROLLAND, MD,PhDemail@example.com|
|Abbeville, France, 80100|
|Contact: Maroussia WILQUIN, MD|
|Centres de Soins, d'Accompagnement et de Prévention en Addictologie (CSAPA) Le Cèdre Bleu||Recruiting|
|Armentières, France, 59280|
|Contact: Marie-Christine BLANQUARD, MD|
|Arras, France, 62000|
|Contact: Dominique LEJEUNE, MD|
|Service d'Aide aux Toxicomanes (SATO-Picardie)||Recruiting|
|Beauvais, France, 60000|
|Contact: Jean-Jacques PIK, MD|
|Boulogne, France, 62200|
|Contact: Frédéric TEISSIERE, MD|
|University Hospital of Caen||Not yet recruiting|
|Contact: François VABRET, MD, PhD|
|Contact: Nicolas CABE, MD|
|Carvin, France, 62220|
|Contact: Hugo FAVRE, MD|
|Clermont, France, 60600|
|Contact: Sophie VELASTEGUI, MD|
|Dunkerque, France, 59300|
|Contact: Cécile RICHEZ, MD|
|Ham, France, 80400|
|Contact: Michel SOCHALA, MD|
|Hazebrouck, France, 59190|
|Contact: Lucie MOLMY, MD|
|Lens, France, 62300|
|Contact: Christelle DUBOCAGE, MD|
|Etablissement Public de Santé Mentale (EPSM)||Recruiting|
|Lille, France, 59000|
|Contact: Véronique VOSGIEN, MD|
|Roubaix, France, 59100|
|Contact: Laurent URSO, MD|
|University Hospital of Rouen||Not yet recruiting|
|Contact: Alexandre BAGUET, MD|
|Saint Pol sur Ternoise, France, 62130|
|Contact: Dominique LEJEUNE, MD|
|Saint-Amand-les-Eaux, France, 59230|
|Contact: Charles LESCUT, MD|
|Tourcoing, France, 59200|
|Contact: Laure SPINOSI, MD|
|Valenciennes, France, 59300|
|Contact: Alexandre BONORD, MD|
|Principal Investigator:||Renaud JARDRI, MD, PhD||CHRU de Lille|